BNB Plus Corp

BNB Plus Corp(BNBX)股票分析

$0.163

-0.093 (-56.75%)收盤時

Loading chart…
High
0.188
Open
0.162
VWAP
0.17
Vol
5.34M
Mkt Cap
Low
0.152
Amount
896.34K
EV/EBITDA, TTM
0.00

BNB Plus Corp., formerly Applied DNA Sciences, Inc., is a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

www.bnbx.io

AI analysis of BNB Plus Corp (BNBX)

sell

BNBX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The price trend is weak, there is no bullish proprietary signal, no recent news catalyst, and sentiment data is neutral to negative. Based on the current setup, the direct opinion is to avoid buying now and not commit capital here.

估值指標

The current forward P/E ratio for BNB Plus Corp (BNBX) is 158.73, compared to its 5-year average forward P/E of 124.34.

Forward P/E

Fair
5Y Average P/E
124.34
Current P/E
158.73
高估
215.53
低估
33.15

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.70
Current P/S
0.00
高估
0.95
低估
0.45

事件時間軸

2026-07-30 (ET)

07:30:00

BNB Plus Concludes Asset Management Agreement with Cypress

2026-07-13 (ET)

08:00:00

BNB Plus Receives Delisting Determination from Nasdaq

2026-05-26 (ET)

08:20:00

BNB Plus Secures $4.1M Convertible Preferred Stock Financing Commitments

2026-04-24 (ET)

09:50:00

NY AG Sues Coinbase and Gemini for Illegal Gambling

2026-04-23 (ET)

07:20:00

Company Board Initiates Strategic Alternatives Review

資訊

BNBX FAQ — answered by Alphio AI

BNB Plus Corp., formerly Applied DNA Sciences, Inc., is a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets. It operates in the Financials sector.

BNBX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The price trend is weak, there is no bullish proprietary signal, no recent news catalyst, and sentiment data is neutral to negative. Based on the current setup, the direct opinion is to avoid buying now and not commit capital here.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始